{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:44:24Z","timestamp":1777934664510,"version":"3.51.4"},"reference-count":31,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100003122","name":"Ferring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003122","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To provide a practical approach to pharmacists regarding the safe and effective use of nadofaragene firadenovec.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>Clinical study data and pharmacist experience in institutional settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data summary<\/jats:title>\n                    <jats:p>This review article discusses the role of pharmacists caring for patients with Bacillus Calmette-Gu\u00e9rin (BCG)\u2013unresponsive non\u2013muscle-invasive bladder cancer (NMIBC) receiving nadofaragene firadenovec. Pharmacist roles in a multidisciplinary care team are described and involve considerations surrounding nadofaragene firadenovec, including its mechanism of action, indication, handling, storage, administration, adverse event profile, disposal, counseling, and other practical points.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pharmacists are positioned to be key contributors to the care team regarding the effective use of nadofaragene firadenovec. Further awareness and education will continue to optimize the clinical use of nadofaragene firadenovec in the high-risk BCG-unresponsive NMIBC setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552251315146","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T01:52:38Z","timestamp":1739843558000},"page":"488-494","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Practical use of nadofaragene firadenovec-vncg for pharmacists"],"prefix":"10.1177","volume":"31","author":[{"given":"Seth D","family":"Holler","sequence":"first","affiliation":[{"name":"WVU Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6078-2767","authenticated-orcid":false,"given":"Sara Moran","family":"Smith","sequence":"additional","affiliation":[{"name":"Allina Health"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"key":"e_1_3_3_4_2","unstructured":"National Cancer Institute. SEER Program. Cancer Stat Facts: Bladder cancer https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html (2021 accessed 21 April 2022)."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.08.010"},{"key":"e_1_3_3_6_2","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Bladder Cancer. Version 4.2024 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf (2024 accessed 07\/08\/2024)."},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003846"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.12.031"},{"key":"e_1_3_3_9_2","article-title":"Intravesical bacillus Calmette-Guerin in Ta and T1 bladder cancer","volume":"2000","author":"Shelley MD","year":"2000","unstructured":"Shelley MD, Court JB, Kynaston H, et al. Intravesical bacillus Calmette-Guerin in Ta and T1 bladder cancer. Cochrane Database Syst Rev 2000; 2000: CD001986.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30540-4"},{"key":"e_1_3_3_11_2","unstructured":"Ferring Pharmaceuticals. ADSTILADRIN\u00ae (nadofaragene firadenovec-vncg) suspension for intravesical use. Kastrup Denmark. 2024."},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/20009666.2020.1742475"},{"key":"e_1_3_3_13_2","unstructured":"Merck Sharp & Dohme LLC. TICE\u00ae BCG (for intravesical use). Rahway NJ. 2022."},{"key":"e_1_3_3_14_2","unstructured":"American Urological Association. BCG Shortage Info https:\/\/www.auanet.org\/about-us\/bcg-shortage-info (2020 accessed 2023)."},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2019.05.018"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67707-5"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005392-199707000-00017"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-159002"},{"key":"e_1_3_3_19_2","unstructured":"US Department of Health and Human Services. BCG-unresponsive nonmuscle invasive bladder cancer: Developing drugs and biologics for treatment guidance for industry https:\/\/www.fda.gov\/media\/101468\/download (2018 accessed 02\/2023)."},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17598"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S274951"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2022.12.016"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/jso.23700"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2014.02.011"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1359725"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000004020"},{"key":"e_1_3_3_27_2","unstructured":"Merck Sharp & Dohme Corp. KEYTRUDA\u00ae (pembrolizumab) injection for intravenous use. Whitehouse Station NJ. 2024."},{"key":"e_1_3_3_28_2","unstructured":"Endo Pharmaceuticals Solutions Inc. VALSTAR\u00ae (valrubicin) solution for intravesical use. Malvern PA. 2016."},{"key":"e_1_3_3_29_2","unstructured":"ImmunityBio Inc. ANKTIVA\u00ae (nogapendekin alfa inbakicept-pmln) solution for intravesical use. Culver City CA. 2024."},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.01.011"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-023-02070-0"},{"key":"e_1_3_3_32_2","volume-title":"StatPearls","author":"Tariq RA","year":"2024","unstructured":"Tariq RA, Vashisht R, Sinha A, et al. Medication dispensing errors and prevention. In: StatPearls. Treasure Island, FL: StatPearls Publishing, 2024."}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251315146","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552251315146","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251315146","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:30:44Z","timestamp":1777689044000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552251315146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1177\/10781552251315146"],"URL":"https:\/\/doi.org\/10.1177\/10781552251315146","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,17]]}}}